Summary
A clinical study of TanderilR in tonsillectomy cases was undertaken with a view to evaluate its anti-flam-matory properties. 32 cases were tried by double blind method and analysed. Analgesic property of oxyphenbutazone was significant. Next in order was the anti-exudative property. The overall supremacy of the drug could not be established unequivocally in this study. This is partly due to the inherent error that is associated with any subjective analysis and partly due to the less number of cases that were studied.
Similar content being viewed by others
References
Jaumann, K. et al. Tanderil in otorhinolaryngology with special consideration of postoperativeoedema. HNO, 11: 332–334, November, 1963.
Teitel, L. H., et al. Oxyphenbutazone, a new anti-inflammatory agent in the treatment of acute otolaryngology disorders Archives of Otolaryngology, Vol. 78, 91–94, July, 1963.
Orecchioni, F. Clinical experience in ENT practice with a new synthetic anti-inflammatory agent. Ann. Laryng. (Torino), 61, 2: 236–243, 1962.
Cancura, W. Clinical trial of a new anti-inflammatory substance G 27 202 in tonsillectomy. Ther. Umsch. 17, 314, 1960
Barcelo, R. et al. Effects of oxyphenbutazone (Tanderil) on plasma seromucoids. I. In Experimental Inflammation. Canad. Med. Ass. J., Vol. 88, 562–567, March 16, 1963.
Author information
Authors and Affiliations
Additional information
Tanderil is the Registered Trade Mark of Messrs. J.R. Geigy, S.A., Basle, Switzerland, being marketed in India by Messrs. Suhrid Geigy Trading Limited, Bombay.
Rights and permissions
About this article
Cite this article
Murthy, M.V.V. Tanderil in tonsillectomy. Ind. J. Otol. 19, 25–29 (1967). https://doi.org/10.1007/BF03047801
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03047801